Decrease Cervidil Utilization for Cervical Ripening
Decrease Cervidil Utilization for Cervical Ripening by 25%
Prostaglandin analogues, dinoprostone and misoprostol are widely used in
"induction of labor" practice for ripening the cervix and stimulating
uterine contractions in order to achieve vaginal delivery. Although dinoprostone
has been approved by the FDA for cervical ripening in women at or near
term, misoprostol has numerous studies showing similar and superior effectiveness.
Misoprostol has the advantage of lower cost, no need for refrigeration
and potentially higher efficacy. Through consensus, the OB Collaborative
in conjunction with the Pharmacy Enterprise implemented a migration from
dinoprostone to misoprostol with a goal of decreasing dinoprostone utilization by 25%.
By migrating from Cervidil to misoprostol the OB Collaborative set a goal
to reduce C-Section rates by 10%